Ab0574 #ACR22: Osteoporosis in Men - Under-recognized? Under-Screened? Under-Diagnosed! @AMollaeianMD: Retrosp study >65 yo <1% M have DEXA compared to 7-10% in F in 2010, 2018, and 2021 Hip fx 4.1% F, 3% M DEXA declined in M between 2010-2018, no change in 2021 🦴🦴🩻 @RheumNow https://t.co/LbmxLnIX1Q

#ACR22 Abstr#0799 Is Evusheld effective in patients on B-cell depleting therapies? Early data (Jan-May 22) from @CCalabreseDO @LCalabreseDO are encouraging: 13/417 (3%) breakthrough infection in fully vac pts, 1 hospitalised. More data needed for Omicron subvariants @RheumNow https://t.co/g4Y1IMO67X

#ACR22 Abstr#0783. Rituximab impacts on humoral immunity. Our study on 400 RMD pts showed: Breakthrough infection 30% mostly mild; Severe 4%; 1 death Poor outcomes predicted by comorbidities & low IgG Risk reduced by 50% with each vac dose OK for RTX if vaccinated @RheumNow https://t.co/xyJsukm1Rh

☝️Remember: Not all skin thickening is SSc! 🔸Lipodermatosclerosis is a differential. Has an inverted champagne bottle appearance - caused by venous stasis and venous HTN #ACR22 @RheumNow #Scleroderma #RheumTwitter https://t.co/joWWn6BnVC

Song et al. Korean study shows better persistence of tocilizumab than TNFi as first-line biologic in RA. No difference in incidence of TB. @RheumNow #ACR22 Abstr#0887 https://t.co/EuQkfDZd77 https://t.co/VxJmKEzAVY

Lanz et al. Inverse relationship between number of ACPAs and subclinical ILD. Effect appears confined to African American and Hispanic participants. Not sure what to make of this at all. @RheumNow #ACR22 Abstr#1203 https://t.co/Ok3PCLFyxe https://t.co/UHlI6HOUmc

Deodhar et al. Bimekizumab (IL-17A/Fi) in nr-axSpA. Efficacy shown across all outcomes. Confirms bimekizumab works across spectrum of axSpA (not surprisingly). @RheumNow #ACR22 Abstr#0544 https://t.co/XVGBgBQpTH https://t.co/39zW5Ex9xh

Hanlon @MeganHanlon4 @dougveale et al. Loss of macrophage homeostasis occurs in pre-RA, and appears to be an early factor in RA development @RheumNow #ACR22 Abstr#0554 https://t.co/UL1jVGVlrA https://t.co/i1WWQlHs2m

Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal progression in AS. But... for high risk patients there may be some benefit - see figure. @RheumNow #ACR22 Abstr#0546 https://t.co/xo9Uy6aX71 https://t.co/vZgaoeEQn4

Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work. 12 months. Only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. @RheumNow #ACR22 Abstr#0545 https://t.co/Fa5YgT9FYk https://t.co/9C8ShI9qjk